https://www.biotron.com.au/wp-content/uploads/2018/10/Shareholder-Update.pdf5th last paragraph… a possible commercial deal was mentioned but didn’t come.
That is why I mentioned I my previous post that the results will need to be good enough to get a deal. You can have positive data but still might not get a deal.
So from the first trial results BP might look at the data and say how about you do this and we will look at it again.
From there investors question the investment and how long they have to wait for a return. Those that wanted a quick win will exit fairly quickly, some will stick around a bit longer but will eventually exit, others will bottom draw and see what happens and some just want to stick around for who knows why….maybe just to have a whinge.
This time around there is 3 studies, HIV with long term ART recipients still with compromised immunity, newly infected HIV similar to first trial, as well as a trial for Covid.
The below contains a bit of an overview / comparison on the 3 HIV trials.
https://www.biotron.com.au/wp-content/uploads/2022/10/Second-BIT225-Phase-2-HIV-1-Clinical-Trial-Fully-Recruited.pdfThe 3 trials completed hopefully will provide more robust data and the indications that BP are looking for. I think the study done in Australia will be pivotal to the outcome, but that is just my thoughts.
Hope this helps.
